Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | GRK2 | P25098 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748254 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTHTTMEN1KMT2A | |
| SCHEMBL30148008 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPTHTTMEN1KMT2A | |
| SCHEMBL6694651 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPTHTTMEN1KMT2A | |
| SCHEMBL13414534 | 0.82 | ALDH1A1 (0.53) | SMN1; SMN2MAPTHTTMEN1KMT2A | |
| SCHEMBL21678086 | 0.82 | ALDH1A1 (0.48) | SMN1; SMN2MAPTMEN1KMT2APOLB | |
| SCHEMBL10034515 | 0.82 | LMNA (0.56) | SMN1; SMN2MAPTMEN1KMT2APOLB | |
| SCHEMBL1887376 | 0.82 | KMT2A (0.59) | SMN1; SMN2MAPTHTTMEN1KMT2A | |
| SCHEMBL9403860 | 0.82 | KDM4E (0.59) | MEN1KMT2APOLBHDAC1HDAC6 | |
| SCHEMBL6779344 | 0.82 | HDAC1 (0.47) | SMN1; SMN2MAPTHTTMEN1KMT2A | |
| SCHEMBL30296233 | 0.82 | KDM4E (0.59) | MEN1KMT2APOLBHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522870-B2 | 2,5-disubstituted-1,4-diaminobenzenes | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2016-12-20 | — | — | US | claimed |
| US-20130237725-A1 | 2,5-DISUBSTITUTED-1,4-DIAMINOBENZENES | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2013-09-12 | — | — | US | claimed |
| JP-6184065-A | — | — | None | — | — | JP | disclosed |
| CN-112513141-B | Polymer for use in electronic devices | 杜邦电子公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20210179665-A1 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF | PARABILIS MEDICINES, INC. | 2021-06-17 | — | — | US | disclosed |
| CN-112513141-A | Polymers for use in electronic devices | 杜邦电子公司 | 2021-03-16 | — | — | CN | disclosed |
| WO-2020041270-A1 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-9546153-B2 | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546153-B2 | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546153-B2 | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2922840-B1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| US-5523277-A | PRE- AND POST-EMERGENCE HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| US-5496954-A | MULTISTEP SYNTHESIS | AMERICAN CYANAMID CO. (US) | 1996-03-05 | — | — | US | disclosed |
| JP-H06184065-A | ANILINE COMPOUND | SUMITOMO CHEM CO LTD | 1994-07-05 | — | — | JP | disclosed |
| EP-0246061-B1 | A BENZOYLUREA DERIVATIVE AND ITS PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-5039331-A | Condensed heterocyclic derivatives and herbicides | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1991-08-13 | — | — | US | disclosed |
| EP-0232080-B1 | BENZOYLUREA COMPOUNDS AND THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-05-16 | — | — | EP | disclosed |
| EP-0304920-A2 | Condensed heterocyclic derivatives, process for their production and herbicides | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-03-01 | — | — | EP | disclosed |
| EP-0246061-A2 | A benzoylurea derivative and its production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-11-19 | — | — | EP | disclosed |
| EP-0232080-A2 | Benzoylurea compounds and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237725-A1 | 2,5-DISUBSTITUTED-1,4-DIAMINOBENZENES | DDT, PARP2, DDX42 | SMN1; SMN2 1683/4885MAPT 4189/4885HTT 2545/4885 |
| US-20210179665-A1 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF | IAPP, VIP, NGLY1 | SMN1; SMN2 2559/4885MAPT 3926/4885HTT 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.